Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-095784
Filing Date
2024-08-13
Accepted
2024-08-13 08:30:22
Documents
76
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q cadl-20240630.htm   iXBRL 10-Q 2333085
2 EX-31.1 cadl-ex31_1.htm EX-31.1 14915
3 EX-31.2 cadl-ex31_2.htm EX-31.2 14927
4 EX-32.1 cadl-ex32_1.htm EX-32.1 8216
5 EX-32.2 cadl-ex32_2.htm EX-32.2 8613
  Complete submission text file 0000950170-24-095784.txt   7846766

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cadl-20240630.xsd EX-101.SCH 1086657
79 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20240630_htm.xml XML 1047555
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

EIN.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40629 | Film No.: 241198923
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)